The drug store operator reported earnings of $1.13 a share for the second quarter, beating the Capital IQ Consensus Estimate of $1.10 a share by 3 cents. Revenue grew 10.7% from the year-ago quarter to $34.6 billion. Analysts expected revenue of $33.47 billion for the quarter.
CVS raised its earnings forecast for the full-year 2014 to between $4.43 and $4.51, up from its previous guidance of $4.36 to $4.50 a share. Analysts expect earnings of $4.46 a share for the year.
Must read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreet Ratings team rates CVS CAREMARK CORP as a Buy with a ratings score of A+. TheStreet Ratings Team has this to say about their recommendation: "We rate CVS CAREMARK CORP (CVS) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins." CVS data by YCharts STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.